跳至主要内容
临床试验/NCT03694470
NCT03694470已完成不适用

Retrospective Study to Describe Characteristics of Patients With Type 2 Diabetes Mellitus Who Were Initiating Use or Treatment With Sodium-glucose Co-transporter-2 Inhibitors and Other Diabetes Medications (Other Glucose Lowering Drugs) in 2015-17 Based on National Russian Diabetes Registry Data

AstraZeneca1 个研究点 分布在 1 个国家目标入组 10,000 人开始时间: 2018年4月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
10,000
试验地点
1
主要终点
The proportion of patients who were new users of SGLT-2 inhibitors in 2015, 2016, 2017

研究概览

简要总结

This observational retrospective study will describe characteristics of patients with type 2 diabetes mellitus (T2DM) who were initiating use or treatment with sodium-glucose co-transporter-2 (SGLT-2) inhibitors and other diabetes medications (other glucose lowering drugs) in 2015-17 based on National Russian Diabetes Registry data.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

The proportion of patients who were new users of SGLT-2 inhibitors in 2015, 2016, 2017

时间窗: 2015-2017

The proportion of patients who were new users of SGLT-2 inhibitors in 2015, 2016 2017 among T2DM patients initiated use of antidiabetic treatment in these years according to Russian National Diabetes Registry data.

次要结局

  • Number of participants with co-morbidities(2015-2017)
  • Number of participants with abdominal laboratory values(2015-2017)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验